Edition:
United Kingdom

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

93.65EUR
2:49pm BST
Change (% chg)

€0.75 (+0.81%)
Prev Close
€92.90
Open
€92.90
Day's High
€93.75
Day's Low
€92.55
Volume
37,577
Avg. Vol
135,555
52-wk High
€155.95
52-wk Low
€91.35

Select another date:

Mon, Feb 25 2019

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

PARIS French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion (£1 billion), the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion

PARIS French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

UPDATE 2-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

* Takeover worth up to $1.31 billion (Adds share price reaction and analyst comment)

RPT-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

PARIS, Feb 25 French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

PARIS, Feb 25 French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Select another date: